Balchem Co. (NASDAQ:BCPC) SVP Sells $297,934.05 in Stock

Balchem Co. (NASDAQ:BCPCGet Free Report) SVP Michael Robert Sestrick sold 1,929 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $154.45, for a total transaction of $297,934.05. Following the sale, the senior vice president now directly owns 4,878 shares in the company, valued at approximately $753,407.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Robert Sestrick also recently made the following trade(s):

  • On Wednesday, February 21st, Michael Robert Sestrick sold 11,100 shares of Balchem stock. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00.

Balchem Trading Up 0.7 %

Shares of Balchem stock opened at $156.36 on Thursday. The business has a 50 day moving average price of $150.88 and a 200 day moving average price of $142.53. The company has a market capitalization of $5.07 billion, a P/E ratio of 44.17, a P/E/G ratio of 3.64 and a beta of 0.72. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.61 and a quick ratio of 1.72. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $159.52.

Balchem (NASDAQ:BCPCGet Free Report) last issued its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The business had revenue of $228.70 million for the quarter, compared to the consensus estimate of $234.66 million. During the same period in the prior year, the business earned $0.66 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis. Sell-side analysts anticipate that Balchem Co. will post 3.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Balchem

Institutional investors have recently modified their holdings of the company. Heritage Wealth Management LLC acquired a new stake in shares of Balchem in the fourth quarter worth approximately $226,000. DekaBank Deutsche Girozentrale increased its holdings in shares of Balchem by 71.0% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 51,300 shares of the basic materials company’s stock worth $7,662,000 after buying an additional 21,300 shares during the last quarter. Sei Investments Co. raised its position in shares of Balchem by 7.0% in the 3rd quarter. Sei Investments Co. now owns 121,530 shares of the basic materials company’s stock worth $15,075,000 after buying an additional 7,973 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Balchem in the 3rd quarter worth $465,000. Finally, Congress Asset Management Co. MA boosted its holdings in Balchem by 32.5% in the third quarter. Congress Asset Management Co. MA now owns 225,303 shares of the basic materials company’s stock valued at $27,947,000 after acquiring an additional 55,203 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on BCPC. HC Wainwright boosted their target price on Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, May 6th. StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a research report on Friday, May 10th.

Get Our Latest Stock Report on BCPC

Balchem Company Profile

(Get Free Report)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

Recommended Stories

Insider Buying and Selling by Quarter for Balchem (NASDAQ:BCPC)

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.